Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development

August 17, 2026

Las Vegas Sun News (via Business Wire) USA

Overview

Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Canada facility. This strategic investment bolsters its comprehensive biologics services, addressing rising demand for flexible process development and scale-up for both non-HPAPI and HPAPI programs. By integrating ADC linker and payload production with existing mAb and sterile fill-finish capabilities, Eurofins CDMO Alphora aims to offer fully integrated ADC development, streamlining customer timelines and supply chains.

In Depth

Strategic Expansion Targets Integrated ADC Manufacturing

Eurofins CDMO Alphora has announced a substantial expansion of its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its facility in Mississauga, Canada. This significant investment is designed to meet escalating customer demand and, crucially, to reinforce the company’s fully integrated service offerings for the manufacturing of next-generation bioconjugate therapeutics, particularly Antibody-Drug Conjugates (ADCs).

Advanced HPAPI and Kilolab Capabilities Bolster End-to-End Solutions

The expansion significantly enhances Eurofins CDMO Alphora’s flexibility and capacity for process development, scale-up, and GMP (Good Manufacturing Practice) manufacturing, ranging from gram to kilogram scales. The newly enhanced HPAPI-capable facilities are critical for the synthesis and production of ADC payloads—potent cytotoxic drugs—and linkers. Given the extreme potency of these drug substances, their manufacture demands stringent containment and safety measures. Eurofins CDMO Alphora already offers a broad spectrum of biologics capabilities, including the development and manufacturing of monoclonal antibodies (mAbs) and other proteins, alongside sterile fill-finish services. By bolstering its manufacturing capacity for both the antibody component and the drug component (payload and linker) of ADCs, this expansion empowers the company to provide customers with an ‘antibody to final ADC formulation’ end-to-end integrated solution. This comprehensive approach is designed to eliminate the complexities of managing multiple vendors, accelerate development timelines, and reduce overall supply chain complexities for clients.

Industry Context: Addressing Bottlenecks in the Booming ADC Market

Antibody-Drug Conjugates (ADCs) are rapidly emerging as one of the most promising modalities in cancer treatment, requiring highly specialized expertise and facilities for their development and manufacturing. ADCs are comprised of three key elements: a targeted antibody, a potent cytotoxic payload, and a stable linker that connects the two. The high potency of the payloads, in particular, necessitates specialized facilities and rigorous safety standards for their handling. As the ADC pipeline has expanded in recent years, global demand for specialized Contract Development and Manufacturing Organizations (CDMOs) has surged, yet supply remains limited. The expansion of HPAPI and ADC manufacturing capabilities by companies like Eurofins CDMO Alphora is therefore crucial for alleviating these market bottlenecks and accelerating the delivery of groundbreaking cancer therapeutics to patients.

Future Outlook: Accelerating Next-Generation Bioconjugate Therapies

Eurofins CDMO Alphora’s expanded capabilities are poised to play a pivotal role in accelerating the development and manufacturing of next-generation ADCs and other high-potency bioconjugate therapeutics. The integrated service offering will enable pharmaceutical companies to seamlessly transition from R&D stages through to commercialization, ultimately enhancing overall efficiency and cost-effectiveness. This strategic investment is expected to support the sustained growth of the ADC market and contribute significantly to the development of safer and more effective cancer treatments. The industry will keenly watch for the new ADC projects that the company will support and its contributions to the market moving forward.

Source: https://lasvegassun.com/news/2026/aug/13/eurofins-cdmo-alphora-expands-kilolab-and-high-pot/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.